prof. dr. H.M. (Helena) Verkooijen

prof. dr. H.M. (Helena) Verkooijen

Full Professor
prof. dr. H.M. (Helena) Verkooijen
  • Clinical Trial Office

Research Programs

Strategic Program Cancer



Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.

Director of Research at the division of Imaging and Oncology of the UMC Utrecht. Project leader of several international (Horizon) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member. 

Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).


Side Activities


  • Member Supervisory Board Oogziekenhuis Rotterdam
  • Member evaluation committee Dutch Cancer Foundation
  • Chair Steering Committe Center of Excellence of the Focused Ultrasound Foundation
  • Member Scientific Advisory Board Dutch Expert Centre for Screening
  • Board Member J.M. Fentener van Vlissingen Fonds

Research Output (395)

Realizing the value of complex medical technology:Demonstrating cost-effectiveness is not enough

Hehakaya C., Frederix G. W.J., van der Voort van Zyp J. RN, Grobbee D. E., Verkooijen H. M. Jul 2023, In: Clinical and translational radiation oncology. 41

Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR):protocol of a phase I dose-escalation trial

Verweij Maaike E, Tanaka Max D, Kensen Chavelli M, van der Heide Uulke A, Marijnen Corrie A M, Janssen Tomas, Vijlbrief Tineke, van Grevenstein Wilhelmina M U, Moons Leon M G, Koopman Miriam, Lacle Miangela M, Braat Manon N G J A, Chalabi Myriam, Maas Monique, Huibregtse Inge L, Snaebjornsson Petur, Grotenhuis Brechtje A, Fijneman Remond, Consten Esther, Pronk Apollo, Smits Anke B, Heikens Joost T, Eijkelenkamp Hidde, Elias Sjoerd G, Verkooijen Helena M, Schoenmakers Maartje M C, Meijer Gert J, Intven Martijn, Peters Femke P 15 Jun 2023, In: BMJ Open. 13 , p. 1-10

Defining the role of real-world data in cancer clinical research:The position of the European Organisation for Research and Treatment of Cancer

Saesen Robbe, Van Hemelrijck Mieke, Bogaerts Jan, Booth Christopher M, Cornelissen Jan J, Dekker Andre, Eisenhauer Elizabeth A, Freitas André, Gronchi Alessandro, Hernán Miguel A, Hulstaert Frank, Ost Piet, Szturz Petr, Verkooijen Helena M, Weller Michael, Wilson Roger, Lacombe Denis, van der Graaf Winette T Jun 2023, In: European Journal of Cancer. 186 , p. 52-61 10 p.

The use of red flags during the referral chain of patients surgically treated for symptomatic spinal metastases

van Tol Floris R, Kamm Isabelle M L P, Versteeg Anne L, Suijkerbuijk Karijn P M, Verkooijen Helena M, Oner Cumher, Verlaan Jorrit-Jan Jun 2023, In: Neuro-Oncology Practice. 10 , p. 301-306 6 p.

Timing of rectal cancer surgery after short-course radiotherapy:national database study

Verweij Maaike E, Franzen Jolien, van Grevenstein Wilhelmina M U, Verkooijen Helena M, Intven Martijn P W 12 May 2023, In: The British journal of surgery. 110 , p. 839-845 7 p.

Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases:a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design

Huele E H, van der Velden J M, Kasperts N, Eppinga W S C, Grutters J P C, Suelmann B B M, Weening A A, Delawi D, Teunissen S C C M, Verkooijen H M, Verlaan J J, Gal R 4 May 2023, In: Trials. 24

Late gevolgen van radiotherapie na borstkanker

Batenburg Marilot, Accord-Maass Saskia, van der Leij Femke, Verkooijen Helena May 2023, In: Huisarts en Wetenschap. 66 , p. 23-27 5 p.

Feasibility and first results of the 'Trials-within-Cohorts' (TwiCs) design in patients undergoing radiotherapy for lung cancer

Tomassen Mathijs L, Damen Pim J J, Verkooijen Helena M, Peters Max, van der Stap Janneke, van Lindert Anne S R, Verhoeff Joost J C, van Rossum Peter S N 16 Mar 2023, In: Acta Oncologica. 62 , p. 237-244 8 p.

Patient preferences for treatment modalities for localised prostate cancer

Teunissen Frederik R, Hehakaya Charisma, Meijer Richard P, van Melick Harm H E, Verkooijen Helena M, van der Voort van Zyp Jochem R N Mar 2023, In: BJUI compass. 4 , p. 214-222 9 p.

Hyperbaric oxygen therapy for local late radiation toxicity in breast cancer patients:A systematic review

Meier E L, Mink van der Molen D R, Lansdorp C A, Batenburg M C T, van der Leij F, Verkooijen H M, Boonstra O, Hummelink S, Ulrich D J O Feb 2023, In: The Breast. 67 , p. 46-54 9 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet